01—Abstract
Summary
Summary of the 8-K filed January 14, 2026. Cited figures are marked; the original filing is the authoritative source.
Biogen Inc. has filed an 8-K report providing preliminary unaudited estimates for its fourth quarter of 2025 financial results.
The company anticipates a significant charge of approximately $222 milliona on a pre-tax basis related to acquired in-process research and development, upfront, and milestone expenses. This is expected to reduce both GAAP and non-GAAP net income per diluted share by roughly $1.26.
Investors should note that these are preliminary estimates and subject to change as financial closing procedures are completed. The company emphasizes the forward-looking nature of these statements and the inherent risks and uncertainties associated with such projections, urging investors to consult detailed risk factors in their SEC filings.
02—Key points
Key Highlights
- Biogen expects to record approximately $222 million in acquired in-process R&D, upfront, and milestone expenses for Q4 2025.
- This expense is estimated to reduce Q4 2025 GAAP and non-GAAP EPS by approximately $1.26 per share.
- These are preliminary estimates and subject to completion of financial closing procedures.
- The company categorizes these expenses separately in its income statements since Q1 2025.
- Biogen does not forecast these expenses due to their inherent uncertainty in timing and magnitude.
- Investors are cautioned about the forward-looking nature and potential inaccuracies of these estimates.
03—Questions
Frequently Asked Questions
What is the main financial impact reported in this 8-K filing?
The main impact is an anticipated charge of approximately $222 million (pre-tax) for acquired in-process research and development, upfront, and milestone expenses in the fourth quarter of 2025. This is expected to decrease earnings per share by about $1.26 on both a GAAP and non-GAAP basis.
Are these final results for the fourth quarter of 2025?
No, these are preliminary, unaudited estimates. The results are not yet finalized and are subject to the company's financial statement closing procedures. Actual results may differ from these estimates.
Why is Biogen incurring these R&D and milestone expenses?
These expenses are related to collaboration and license agreements, including upfront and milestone payments, and potentially premiums on equity securities or asset acquisitions of in-process R&D. The specific details of the underlying transactions are not provided in this filing.
Why does Biogen not forecast these types of expenses?
Biogen does not forecast acquired in-process R&D, upfront, and milestone expenses because of the significant uncertainty surrounding the future occurrence, magnitude, and timing of these types of transactions.
04—Continue